Abstract: The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD).

Abstract: The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.

Abstract: The present invention relates a mobile terminal, a watch-type mobile terminal and a method of controlling therefor. More specifically, the present invention relates to a method of playing a video by streaming according to data capacity allocated to the mobile terminal or the watch-type mobile terminal.

Abstract: The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclohexylmethanisoindol-1,3-dione and intermediates thereof.

Abstract: The present invention relates to Saroglitazar free acid of Formula (IA) or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable esters, stereoisomers, tautomers, analogs and derivatives thereof. The present invention also provides an amorphous form of saroglitazar free acid and processes of preparation thereof. The present invention also provides pharmaceutical composition comprising an amorphous form saroglitazar magnesium.

Abstract: The present invention relates to an improved process for the preparation of pyrroles derivatives having hypolipidemic and hypocholesteremic activities. In particular, the invention relates to an improved process for the preparation of 2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also relates to an improved process for the preparation of mesylate compound (A1).

Abstract: The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.

Abstract: The present invention provides crystalline form of intermediates of Formula 2A, The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.

Abstract: A method and system for migration of multi-tier virtual application across different clouds hypervisor platforms. The principal object of the embodiment is to provide migration of multi-tier virtual application from one vendor to another vendor cloud platforms. Another object of the embodiment is to convert entire multi-tier virtual application of a source vendor cloud platforms, along with the virtual machines, configuration and properties into a format suitable for a destination vendor cloud platforms. Another object of the embodiment is to verify the migrated application after completion of conversion and migration.

Abstract: The present invention relates to bioactive extracts its fractions and isolation of compound from Rauwolfia tetraphylla. The extracts and fractions are useful for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and Serotonergic (5HT2A) receptors for antipsychotic activity. The present invention relates to novel antipsychotic activity in the leaf alkaloids of Formula 1 and 2 named tetrahydroalstonine, 10-methoxytetrahydroalstonine, isoreserpiline, 10-demethoxyreserpiline, 11-demethoxyreserpiline, reserpiline and ?-yohimbine. The present invention also relates to processes for obtaining antipsychotic extracts as well as for the isolation of alkaloids of formula 1 and 2 from the leaves of Rauwolfia tetraphylla. The present invention particularly relates to significant antipsychotic activity in the MeOH extract, ethylacetate and chloroform fractions of R.

Abstract: Embodiments herein provide a method and system to create an optimized test suite for software testing. This system fetches required input parameters such as risk parameters, release type of the application, requirement details, test case details, requirement to test case relation and so on automatically using any suitable tool. Then, first level optimized test suite is formed by removing redundant and obsolete test cases from test case set. Further, probability of failure is calculated for each test case either manually or through automation and risk index value for each test case is defined. Further, test cases are classified based on value of risk index obtained. Further, second level optimized test suite is formed by using orthogonal array methodology. Furthermore, final optimized test suite with greater precision is prepared by considering execution time of iteration of all test cases along with their risk index values.

Abstract: The present invention discloses process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexyl-methan-isoindol-1,3-dione and intermediates thereof.

Abstract: The present invention provides crystalline form of intermediates of Formula 2A, The present invention also provides process for the preparation of dabigatran etexilate mesylate; polymorph of intermediates thereof; particularly processes for the preparation of crystalline form of intermediates. The present invention also relates to the use of crystalline intermediates for the preparation of dabigatran etexilate mesylate.

Abstract: Enabling search in a touchscreen device. This embodiment relates to electronic devices, and more particularly to electronic devices with a touchscreen. The principal object of this embodiment is to enable a user to perform a search in a text based data in a single step on a touch screen based device.

Abstract: The present invention provides a solid state Form-Z of 5-(4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide. The present invention also provides a process for preparing Form-Z of 5-(4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl)benzofuran-2-carboxamide comprising the steps of i) reacting solid state form of 5-(1-piperazinyl)benzofuran-2-carboxamide or its salts with 3-(4-chlorobutyl)-1H-indole-5-carbonitrile an organic solvent in presence of a base to obtain crude vilazodone free base; ii) purifying the crude vilazodone free base of step (i) in an organic solvent; iii) treating the purified vilazodone free base of step (ii) with an organic solvent to obtain solid state form-Z of vilazodone. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of vilazodone hydrochloride and use of solid state Form-Z of vilazodone for the treatment of major depressive disorders.

Abstract: The embodiments herein relate to web searches and, more particularly, to a gaze controlled approach to automate web search. The system identifies coordinates of the display unit the user is gazing at, at each instance of time and forms corresponding gaze vectors. Further, data displayed on the display unit is grouped into different semantic zones; with each semantic zone having different coordinates. By comparing coordinate information in the gaze vector and each of the semantic zones, the system identifies semantic zone the user is gazing at. Further, from the identified semantic zones, the system identifies a subject of interest for that user. A search is performed in the associated databases with the subject of interest as the key and the results are displayed to the user.

Abstract: A method and system for migration of multi-tier virtual application across different clouds hypervisor platforms. The principal object of the embodiment is to provide migration of multi-tier virtual application from one vendor to another vendor cloud platforms. Another object of the embodiment is to convert entire multi-tier virtual application of a source vendor cloud platforms, along with the virtual machines, configuration and properties into a format suitable for a destination vendor cloud platforms. Another object of the embodiment is to verify the migrated application after completion of conversion and migration.

Abstract: The present invention relates to an amorphous form of vilazodone hydrochloride and process for the preparation of amorphous form of vilazodone hydrochloride. The invention also relates to pharmaceutical compositions that include a therapeutically effective amount of the amorphous form of vilazodone hydrochloride and use of said compositions for the treatment of major depressive disorder (MDD).

Abstract: Systems and methods are provided that comprise a security policy verification system for verifying security policies. The system parses programming language code that implements security policies, and identifies annotations in the programming language code. The system then matches the annotations to the security policies to which the annotations correspond. The system then displays a natural language description of the security policy in a user interface.

Abstract: The present invention relates to bioactive extracts its fractions and isolation of compound from Rauwolfia tetraphylla. The extracts and fractions are useful for the treatment of psychosis based on in-vivo validation on animal model and proportional binding affinities for dopaminergic-D2, Cholinergic (muscarinic) and Serotonergic (5HT2A) receptors for antipsychotic activity. The present invention relates to novel antipsychotic activity in the leaf alkaloids of Formula 1 and 2 named tetrahydroalstonine, 10-methoxytetrahydroalstonine, isoreserpiline, 10-der?ethoxyreserpiline, 11-demethoxyreserpiline, reserpiline and ?-yohimbine. The present invention also relates to processes for obtaining antipsychotic extracts as well as for the isolation of alkabids of formula 1 and 2 from the leaves of Rauwolfia tetraphylla. The present invention particularly relates to significant antipsychotic activity in the MeOH extract, ethylacetate and chloroform fractions of R.